Medtronic + Shanghai Lingang Special Area
Medtronic
Minneapolis, Minnesota · 2 relationships
Active relationship
Government Partnership · 2021–present
Shanghai Lingang Special Area
Shanghai, Shanghai · 2 relationships
Analysis
On October 12, 2021, Medtronic signed an investment agreement with the Lingang Special Area Administration and Shanghai Lingang Fengxian Economic Development to establish a medical-technology industry base in Shanghai's Lingang Special Area. Medtronic said the project would use its international medical-technology development experience to establish high-end, intelligent medical-device research, development and production services, while local officials described the agreement as part of Lingang's Life Blue Bay precision-medicine cluster. [1]
The project was designed around cardiovascular devices and local value-chain development. Yicai reported in February 2022 that the initial phase was expected to receive approximately CNY300 million, or about $47.2 million at the time, with construction expected to begin in June and be completed within five years. The same report said annual output capacity was expected to reach about CNY300 million in the third year of operation; these are project projections rather than audited partnership revenue. [2]
The Lingang base also represented a change in Medtronic's China manufacturing strategy. Contemporary reporting characterized it as Medtronic's first investment in core-business manufacturing in China and said the company planned localized research and development and production for high-end product lines. A Shanghai government account said construction began in late 2022 and that the base was expected to become operational in 2024, alongside Medtronic's two Chinese innovation centers in Shanghai and Chengdu. [2] [3]
Later public reporting indicates that the project progressed into production and clinical use. In 2024, a Lingang-linked account said Medtronic's first production line had launched in 2023; in April 2026, the Lingang government reported that MyanCor, a wholly owned Medtronic subsidiary in the area, had completed clinical implantation of its cardiac pacemakers at multiple Chinese sites. The government described this as a localized chain spanning research and development, production and clinical application, with additional arrhythmia therapies expected to be localized. [4] [5]
Participants
Continue through either entity
Minneapolis, Minnesota · 2 records in this database
Medtronic was founded in Minneapolis in 1949 by electrical engineer Earl Bakken and his brother-in-law, Palmer Hermundslie, as a business repairing medical electronics. The company’s history describes the early operation as a small workshop that expanded from repairs into custom medical equipment, with the founders’ engineering work closely connected to clinicians and hospitals. [1] [2]
A power outage in Minneapolis on Halloween 1957 exposed the risks of the bulky, outlet-powered pacemakers then used after open-heart surgery. At the request of University of Minnesota heart surgeon C. Walton Lillehei, Bakken developed a wearable, battery-operated pacemaker within four weeks; Medtronic’s history says the company produced its first implantable pacemaker one year later, while a separate company account identifies commercialization of the first implantable pacemaker in 1960. [1] [2]
Medtronic has since developed a broad medical-technology portfolio. Its current key-facts page says its technologies address more than 70 health conditions through cardiovascular, medical-surgical and neuroscience portfolios, including electrophysiology, interventional cardiology, peripheral vascular health, acute care and monitoring, endoscopy, surgery, cranial and spinal technologies, neuromodulation and neurovascular care. The page reports FY25 figures of 174 active clinical trials, $2.7 billion in research-and-development investment and more than 41,000 active patent matters. [3]
The company’s current corporate structure also reflects its international scale. Following the 2014 agreement to acquire Covidien, Medtronic said Medtronic plc would be the parent company, with principal executive offices in Ireland and operational headquarters in Minneapolis. This supports retaining Minneapolis as the operational headquarters in the entity record while distinguishing it from the parent company’s Irish administrative headquarters. [4]
Medtronic’s inclusion in this database is associated with its medical-technology partnerships and clinical ecosystem, but its own identity is rooted in engineering-led device development. The company’s current key-facts page says its technologies have served more than 74 million patients and that its mission is pursued through products and therapies spanning the three listed solution portfolios. [3]
Shanghai, Shanghai · 2 records in this database
Lin-gang Special Area is a geographic and administrative area within the China (Shanghai) Pilot Free Trade Zone, not a single operating company. Its official overview places it south of the Dazhi River and south of Pudong International Airport; initial development covers Nanhui New Town, Lin-gang Equipment Industrial Zone, Xiaoyangshan Island and the southern part of Pudong airport. The area sits between Pudong airport and Yangshan International Port and is administered through a dedicated Lin-gang administration. [1]
Shanghai’s 2025 review says Lin-gang was established in 2019 and had introduced more than 679 key projects in frontier-technology industries, attracting over RMB730 billion in investment. The same official account reports average annual growth of industrial output above designated size of 28.4 percent, while integrated circuits, civil aviation, biopharmaceuticals and artificial intelligence recorded a combined average annual growth rate of 38.3 percent; the IC sector’s six-year average growth exceeded 50 percent. [2]
The area’s policy role is expressed through institutional experiments as well as industrial development. An official 2025 account reports 166 institutional-innovation cases, including 79 national firsts, and says a Yangshan Free Trade Zone customs policy cut overall clearance time from two days to two hours and reduced costs by 50 percent. Lin-gang’s 2025 business-environment agenda also targeted cross-border and offshore finance, trade, data, healthcare and shipping services. These measures frame Lin-gang as a coastal testbed linking trade facilitation, technology commercialization and advanced manufacturing. [3] [4]